Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Targan SR, et al. Among authors: rutgeerts pj. Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21. Gastroenterology. 2007. PMID: 17484865 Clinical Trial.
Challenges in Crohn's disease.
Rutgeerts PJ. Rutgeerts PJ. Rev Gastroenterol Disord. 2004;4 Suppl 3:S1-2. Rev Gastroenterol Disord. 2004. PMID: 15580147 No abstract available.
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. Vande Casteele N, et al. Among authors: rutgeerts pj. Gut. 2015 Oct;64(10):1539-45. doi: 10.1136/gutjnl-2014-307883. Epub 2014 Oct 21. Gut. 2015. PMID: 25336114 Free PMC article. Clinical Trial.
Adalimumab induces deep remission in patients with Crohn's disease.
Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Colombel JF, et al. Among authors: rutgeerts pj. Clin Gastroenterol Hepatol. 2014 Mar;12(3):414-22.e5. doi: 10.1016/j.cgh.2013.06.019. Epub 2013 Jul 12. Clin Gastroenterol Hepatol. 2014. PMID: 23856361 Clinical Trial.
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. D'Haens GR, et al. Among authors: rutgeerts pj. Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1. Aliment Pharmacol Ther. 2017. PMID: 28568974 Clinical Trial.
98 results